Upstream Bio, Inc. cash flow to debt ratio of -10.50K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Upstream Bio, Inc.'s free cash flow has decreased 123.30% from $-59.68M last year to $-133.28M, signaling decreasing performance

Upstream Bio, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Upstream Bio, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Upstream Bio, Inc. has a net cash position, so leverage is healthy.

Upstream Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Upstream Bio, Inc.'s profit margin has decreased (87.00%) in the last year from -2.65K% to -4.96K%, signaling decreasing performance

Upstream Bio, Inc.'s short-term assets of $351.80M exceed its short-term liabilities of $13.45M

Upstream Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Upstream Bio, Inc.'s return on equity of -48.40%, is lower than 15.00%, indicating bad performance

Upstream Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Upstream Bio, Inc. has insufficient public price history to evaluate earnings stability.

Upstream Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Upstream Bio, Inc. has negative free cash flow, indicating cash burn

Upstream Bio, Inc.'s yearly earnings has decreased 128.39% since last year from $-62.81M to $-143.44M, signaling decreasing performance

Upstream Bio, Inc.'s yearly revenue has increased 20.42% since last year from $2.37M to $2.85M, signaling increasing performance

ROIC -62.51% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Upstream Bio, Inc.'s 3-year revenue CAGR of 33.04% is positive, indicating growing revenue over the past 3 years

Upstream Bio, Inc. has insufficient public price history to evaluate revenue consistency.

Upstream Bio, Inc. has insufficient public price history to evaluate ROE consistency.

Upstream Bio, Inc. has insufficient data to evaluate this check.

Upstream Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Upstream Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Upstream Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Upstream Bio, Inc. has insufficient data to evaluate this check.

Upstream Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Upstream Bio, Inc. has a price-to-book ratio of 1.50x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Upstream Bio, Inc. has a price-to-sales ratio of 128.50x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue